Room: AAPM ePoster Library
Purpose: Pancreatic cancer is one of the leading causes of cancer mortality. Radiation therapy is one of the treatment options for pancreatic cancer and the purpose of this study is to quantify the in vitro dose enhancement using gold nanoparticles (GNPs) in the pancreatic cancer cell line, BxPC-3, irradiated with a novel 2.5 MV beam and a clinical 6 MV beam.
Methods: The BxPC-3 pancreatic adenocarcinoma cells were irradiated in the absence and presence of 10
µg/mL bare 50 nm spherical GNPs. The cells were allowed to adhere to a 35 mm diameter well plate, incubated with GNPs for 24 h and washed three times with phosphate buffer saline (PBS) immediately before irradiation. The cells were irradiated at doses of 0, 1, 2 and 4 Gy using 2.5 MV and 6 MV photon beams. Electronic equilibrium was ensured by surrounding the cell plates with a custom bolus placed between solid water. The cells were counted and seeded after radiation and allowed to grow. After 14 days, the cells were fixed with ethanol and stained with methylene blue and clonogenic assays were performed and cell survival curves created.
Results: A comparison of the survival curves of cells injected with 10 µg/mL of GNPs for the 2.5 MV beam show, on average, a twofold dose enhancement relative to no GNPs. The relative survival fractions of cells injected with gold versus no gold for the 6 MV treatment is near unity.
Conclusion: There is potential for dose enhancement using GNPs in pancreatic cancer adenocarcinoma with a non-traditional megavoltage 2.5 MV photon beam. The dose enhancement observed with the 2.5 MV beam is hypothesized to be from the lower beam energy. Future studies involve varying the concentration of GNPs injected to determine the optimal concentration for cell killing.
Not Applicable / None Entered.